Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
07:00am, Wednesday, 18'th Sep 2024
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
01:04pm, Monday, 16'th Sep 2024
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 y
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
08:00am, Monday, 16'th Sep 2024
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.
GSK cancer drugs fast-tracked by Chinese
03:05am, Friday, 13'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in Chin
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
12:41pm, Thursday, 12'th Sep 2024
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
07:15am, Thursday, 12'th Sep 2024
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's
GSK enjoys success with mRNA flu vaccine trial
03:43am, Thursday, 12'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with
GSK's mRNA flu vaccine programme to proceed to late-stage trials
02:22am, Thursday, 12'th Sep 2024
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progres
GSK 'clouds' blowing over suggests Berenberg
06:11am, Wednesday, 11'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a 'buy' at broker Berenberg, which sees some of the ‘clouds of doubt' that have plagued the pharma group's summer starting to ease. Zantac litigati
GSK herpes vaccine fails in clinical trial
03:25am, Wednesday, 11'th Sep 2024
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so f
GSK's experimental HSV vaccine fails to meet main goal in trial
02:16am, Wednesday, 11'th Sep 2024
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage t
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
10:56am, Monday, 09'th Sep 2024
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
GSK drug promotes ‘significant and clinically meaningful reduction' in asthma symptoms
10:31am, Monday, 09'th Sep 2024
British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress, highlighting a 54% reduction in severe asth
GSK sees positive COPD trial results
03:30am, Friday, 06'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD). The trial met its prim
GSK's asthma drug Nucala meets main goal in smoker's lungs trial
02:17am, Friday, 06'th Sep 2024
British drugmaker GSK on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs.
